Get the Stockscreener App
47.30
2.60%
1.20
After Hours:
47.30
Palvella Therapeutics Inc stock is traded at $47.30, with a volume of 190.64K.
It is up +2.60% in the last 24 hours and up +70.76% over the past month.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$46.10
Open:
$47.12
24h Volume:
190.64K
Relative Volume:
1.51
Market Cap:
$522.93M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+15.65%
1M Performance:
+70.76%
6M Performance:
+141.94%
1Y Performance:
+0.00%
1-Day Range:
$44.24
$47.97
1-Week Range:
$40.22
$47.97
52-Week Range:
$11.17
$47.97
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
125 STRAFFORD AVE, WAYNE
Compare PVLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
47.30 | 509.67M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
How to track smart money flows in Palvella Therapeutics Inc.Options Play & Community Consensus Picks - Newser
HC Wainwright Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) Stock - Defense World
Is Palvella Therapeutics Inc. forming a reversal pattern2025 Retail Activity & Free Accurate Trade Setup Notifications - Newser
Chardan Capital Forecasts Strong Price Appreciation for Palvella Therapeutics (NASDAQ:PVLA) Stock - Defense World
Palvella Therapeutics Inc. stock momentum explainedEarnings Recap Summary & Short-Term Swing Trade Alerts - Newser
Detecting price anomalies in Palvella Therapeutics Inc. with AIEarnings Risk Summary & Detailed Earnings Play Alerts - Newser
Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating - 富途牛牛
Palvella Therapeutics price target raised to $75 from $38 at H.C. Wainwright - msn.com
What institutional flow reveals about Palvella Therapeutics Inc.Earnings Summary Report & AI Enhanced Trading Alerts - Newser
Palvella Therapeutics Inc. stock trend forecast2025 Geopolitical Influence & Consistent Profit Trade Alerts - Newser
Exit strategy if you’re trapped in Palvella Therapeutics Inc.Index Update & Safe Entry Zone Tips - Newser
What makes Palvella Therapeutics Inc. stock price move sharplyWeekly Trend Report & Low Drawdown Momentum Ideas - Newser
Palvella Completes Enrollment in Phase 3 SELVA Trial - msn.com
What indicators show strength in Palvella Therapeutics Inc.Trade Ideas & Low Risk Investment Opportunities - Newser
How to read the order book for Palvella Therapeutics Inc.July 2025 Selloffs & Weekly Momentum Picks - Newser
Ranking Palvella Therapeutics Inc. among high performing stocks via toolsMarket Activity Recap & Accurate Technical Buy Alerts - Newser
Visual trend scoring systems applied to Palvella Therapeutics Inc.Portfolio Value Summary & Short-Term Swing Trade Alerts - Newser
Palvella:HC Wainwright Raises Buy Rating, PT to $75 from $38 - AInvest
Will Palvella Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsTake Profit & Intraday High Probability Setup Alerts - Newser
Palvella Therapeutics: Q2 Earnings Snapshot - Norwalk Hour
Risk vs reward if holding onto Palvella Therapeutics Inc.Weekly Profit Report & Low Drawdown Investment Ideas - Newser
Palvella Therapeutics Advances Rare Disease Pipeline - TipRanks
Palvella Posts Cash Gain and Trial Wins - AOL.com
Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price Target - TipRanks
Palvella Therapeutics price target raised to $60 from $45 at Stifel - MSN
Positive Buy Rating for Palvella Therapeutics Driven by Promising Phase 3 Trial Developments and Market Potential - TipRanks
Palvella Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Earnings call transcript: Palvella Therapeutics Q2 2025 shows stock decline - Investing.com
Earnings call transcript: Palvella Therapeutics Q2 2025 shows stock decline By Investing.com - Investing.com Nigeria
Palvella Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Palvella Q2 2025 slides: Strong pipeline progress, shares fall in premarket trading - Investing.com Canada
Palvella Therapeutics (PVLA) Q2 2025 Earnings: Why the Loss Matters Less Than the Phase 3 Trial Momentum - AInvest
Palvella's Skin Disease Drug Shows Promise with 25% Over-Enrolled Phase 3 Trial, Two Key Readouts Ahead - Stock Titan
Will Palvella Therapeutics Inc. stock recover after recent dropMarket Volume Report & Safe Swing Trade Setups - Newser
Palvella Therapeutics Inc. stock volume spike explainedJuly 2025 Outlook & Safe Capital Preservation Plans - Newser
Is Palvella Therapeutics Inc. stock entering bullish territorySecure Buy Strategy Based on Risk Parameters - Newser
How hedge fund analytics apply to Palvella Therapeutics Inc. stockFree Stock Selection With High Accuracy - Newser
Palvella Therapeutics CEO to Speak at Canaccord Genuity Growth Conference - MSN
Palvella Therapeutics (PVLA) to Release Earnings on Thursday - Defense World
Palvella Therapeutics Inc Stock (PVLA) Financials Data
There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):